机构:[a]Zhujiang Hospital, Southern Medical University, Department of Otolaryngology, Guangzhou, China[b]Jinan University, Zhuhai People’s Hospital, Xiangzhou District, Zhuhai, Guangzhou, China[c]University of Science and Technology of China, School of Life Sciences and Medical Center, The Chinese Academy of Sciences Key Laboratory of Innate Immunity and Chronic Diseases, Hefei, China[d]Guangdong Provincial Hospital of Chinese Medicine, Department of Otolaryngology, Guangzhou, China大德路总院珠海院区耳鼻喉科耳鼻喉科广东省中医院[e]The 2nd Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China广东省中医院[f]Jinan University, Department of Biomedical Engineering, Key Laboratory of Biomaterials of Guangdong Higher Education Institutes, Guangzhou, China[g]Guangdong Academy of Medical Sciences, Guangdong General Hospital, Department of Otolaryngology, Guangzhou, China广东省人民医院
Introduction: Serum- and glucocorticoid-inducible kinase 3, a serine/threonine kinase that functions downstream of the PI3K signaling pathway, plays a critical role in neoplastic processes. It is expressed by various tumors and contributes to carcinogenesis. Objective: The objective was to investigate serum- and gtucocorticoid-inducible kinase 3 expression in nasopharyngeal carcinoma, to study the anti-tumor effects of serum- and glucocorticoid-inducible kinase 3 shRNA by inhibiting its expression in nasopharyngeal carcinoma cells and to discuss the potential implications of our findings. Methods: Serum- and glucocorticoid-inducible kinase 3 protein expression in nasopharyngeal carcinoma cell lines (CNE-1, CNE-2, HNE-1, HONE-1, and SUNE-1) and the human immortalized nasopharyngeal epithelium cell line NP69 were assayed by western blotting. Serum- and glucocorticoid-inducibte kinase 3 expression in 42 paraffin-embedded nasopharyngeal carcinoma tissues were performed by immunohistochemistry. MTT assay, flow cytometry, and scratch tests were performed after CNE-2 cells were transfected with the best serum- and glucocorticoid-inducible kinase 3 shRNA plasmid selected by western blotting using lipofectamine to study its effect on cell proliferation, apoptosis, and migration. Results: Serum- and glucocorticoid-inducible kinase 3 was overexpressed in human nasopharyngeal carcinoma tissues and cells. Serum- and glucocorticoid-inducible kinase 3 expression decreased markedly after CNE-2 cells were transfected with the serum- and glucocorticoid-inducible kinase 3 shRNA, leading to strong inhibition of cell proliferation and migration. In addition, the apoptosis rate increased in CNE-2 cells after serum- and glucocorticoid-inducible kinase 3 knockdown. Conclusion: Serum- and glucocorticoid-inducible kinase 3 expression was more frequently observed as the nasopharyngeal epithelium progresses from normal tissue to carcinoma. This suggests that serum- and glucocorticoid-inducible kinase 3 contributes to the multistep process of NPC carcinogenesis. Serum- and glucocorticoid-inducible kinase 3 represents a target for nasopharyngeal carcinoma therapy, and a basis exists for the further investigation of this adjuvant treatment modality for nasopharyngeal carcinoma. (C) 2018 Associacao Brasileira de Otorrinolaringologia e Cirurgia Cervico-Facial. Published by Elsevier Editora Ltda.
基金:
National NaturalScience Foundation of China (no. 81573000, 81260406 and51573071).
第一作者机构:[a]Zhujiang Hospital, Southern Medical University, Department of Otolaryngology, Guangzhou, China
共同第一作者:
通讯作者:
推荐引用方式(GB/T 7714):
Chen Jing,Li Hai Liang,Li Bo Bo,et al.Serum- and glucocorticoid-inducible kinase 3 is a potential oncogene in nasopharyngeal carcinoma[J].BRAZILIAN JOURNAL OF OTORHINOLARYNGOLOGY.2019,85(6):705-715.doi:10.1016/j.bjorl.2018.05.012.
APA:
Chen, Jing,Li, Hai Liang,Li, Bo Bo,Li, Wei,Ma, Dong...&Liu, Tao.(2019).Serum- and glucocorticoid-inducible kinase 3 is a potential oncogene in nasopharyngeal carcinoma.BRAZILIAN JOURNAL OF OTORHINOLARYNGOLOGY,85,(6)
MLA:
Chen, Jing,et al."Serum- and glucocorticoid-inducible kinase 3 is a potential oncogene in nasopharyngeal carcinoma".BRAZILIAN JOURNAL OF OTORHINOLARYNGOLOGY 85..6(2019):705-715